Rimonabant as Acomplia in Europe and Zimulti in the US was developed by Sanofi-Aventis. It is the first-in-class oral selective cannabinoid CB1 receptor antagonist for the treatment of obesity. The ac...
若有任何問題，可使用下方檢索互動介面找解答，或是寫信到客服信箱。
星期一~五 9:00-12:30/13:30-18:00